Skip to main content

Table 4 Design characteristics of AdaPT in comparison to other trials

From: First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation

  VALUE[16] ASCOT-BPLA[17] DREAM[6, 38] AdaPT
  Valsartan Amlodipine Amlodipine Atenolol Ramipril Placebo ACEi Diuretic
  (n = 7649) (n = 7596) (n = 9639) (n = 9618) (n = 2.623) (n = 2.646) (n = 1.353) (n = 662)
Study design RCT RCT RCT Observational study
Endpoint New onset diabetes (secondary objective) New onset diabetes (tertiary objective) New onset diabetes or death (primary endpoint) New onset diabetes (primary evaluation criterion)
Inclusion criteria         
   Age (years) ≥ 50 40–79 ≥ 30 ≥ 45
   Hypertension 160–210/<115 mmHg ≥ 160/100 mmHg n.a. ≥ 140/90 mmHg
   Fasting plasma glucose normal Normal 110–125 mg/dl [6.1–7.0 mmol/l] 110–125 mg/dl [6.1–7.0 mmol/l]
   Impaired glucose tolerance normal Normal 140–199 mg/dl [7.8–11.0 mmol/l] no inclusion criterion
Exclusion criteria         
   Diabetes exclusion (for diabetes endpoint) exclusion (for diabetes endpoint) exclusion exclusion
   Cardiovascular disease possible Possible exclusion possible
Follow-up (years) 4.2 (mean) 5.5 (median) 3.0 (median) 4 (planned)
HR new-onset diabetes 0.77 [95%CI 0.69–0.86] 0.70 [95%CI 0.63–0.78] 0.91 [95%CI 0.80–1.03] n.a.
  1. n.a. = not available